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Advanced therapy medicinal products (ATMPs), including cell therapy products, form a
new class of medicines in the European Union. Since the ATMPs are at the forefront of
scientiﬁc innovation in medicine, speciﬁc regulatory framework has been developed for
these medicines and implemented from 2009. The Committee for Advanced Therapies
(CAT) has been established at the European Medicines Agency (EMA) for centralized clas-
siﬁcation, certiﬁcation and evaluation procedures, and other ATMP-related tasks. Guidance
documents, initiatives, and interaction platforms are available to make the new framework
more accessible for small- and medium-sized enterprises, academia, hospitals, and foun-
dations. Good understanding of the centralized and national components of the regulatory
system is required to plan product development. It is in the best interests of the cell ther-
apy developers to utilize the resources provided starting with the pre-clinical stage.Whilst
there have been no mesenchymal stem cell (MSC)-based medicine authorizations in the
EU, three MSC products have received marketing approval in other regions since 2011.The
information provided on the regulatory requirements, procedures, and initiatives is aimed
at facilitating MSC-based medicinal product development and authorization in the EU.
Keywords: advanced therapy medicinal product, cell therapy medicinal product, mesenchymal stem/progenitor
cell, Committee for AdvancedTherapies, Hospital Exemption, national competent authority
INTRODUCTION
The scientiﬁc progress and advances in the biotechnology sec-
tor have led to the development of therapies which are based
on the use of living cells, recombinant genetic material, and
in vitro engineered tissue. A number of cell therapy and tissue
engineered products have been introduced into the national mar-
kets of several Member States during the last decade. Due to the
novelty, complexity, and technical speciﬁcity of such products,
specially tailored and harmonized rules were necessary to ensure
free movement of those products within the EU. Consequently,
the Regulation (EC) N◦ 1394/2007 on advanced therapy medicinal
products (ATMPs) was drafted and came into force on December
30, 2008. The Regulation laid down speciﬁc rules concerning cen-
tralized authorization, supervision, and pharmacovigilance of the
ATMPs (Committee for Advanced Therapies and CAT Scientiﬁc
Secretariat, 2010).
The term“advanced therapy medicinal product” covers the fol-
lowing medicinal products for human use: somatic cell therapy
medicinal products (CTMPs), gene therapy medicinal products,
and tissue engineered products. Combined ATMPs incorporate
one or more medical devices as an integral part of the product.
The scope of this article is primarily CTMP. For cells to be clas-
siﬁed as medicinal products they have to fulﬁll at least one of
the following conditions: the cells have been subject to substan-
tial manipulation and/or these cells are not intended for use for
the same essential function (the term “non-homologous use” is
also used). By “substantial manipulation” it is understood that
the biological characteristics, functions, or properties relevant for
the therapeutic effect have been altered. Taking into account the
methodological complexity of the cell therapy products, and in
order to reduce the possible interpretations, it has been deﬁned
that certain manipulations with the cells and tissues are not to
be considered as substantial. These include (tissue) cutting, grind-
ing, shaping, centrifugation, soaking in antibiotic or antimicrobial
solutions, sterilization, irradiation, cell separation, concentration
or puriﬁcation, ﬁltering, freezing, cryopreservation, and vitri-
ﬁcation (all listed in the Annex I of the Regulation (EC) N◦
1394/2007). From the scientiﬁc or clinical perspective it can be
argued that cell irradiation, for instance, can have a substantial
effect on the biological characteristics and physiological functions
that may be relevant also for the intended therapeutic application.
Since interpretations by product developer and the regulator may
differ, the exact legal deﬁnition for somatic CTMP is provided in
Table 1.
The requirements for the cell therapyproductmarketing autho-
rization dossier are prescribed in the Directive 2001/83/EC. It has
to be veriﬁed whether the text of the directive includes the amend-
ments introduced until at least 2011. A link to the consolidated
version is provided in the references. Thus, cell therapy require-
ments were introduced in 2010 by the Directive 2009/120/EC
amending the Directive 2001/83/EC. In brief, the particulars and
documents of a cell therapy dossier are presented as ﬁve modules:
Module 1 provides the European Community speciﬁc admin-
istrative data; Module 2 provides the quality, non-clinical, and
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Table 1 | Glossary of key terms for advanced therapy developers in the EU.
Advisory procedures available for ATMP development process:
(a) Classiﬁcation of product by the EMA: optional incentive for applicants, fast procedure, applied preferably during the early development stage;
(b) EMA Innovation Task Force (ITF) brieﬁng meeting: early dialog with product developers with conﬁdential and legally non-binding advice; the NCAs of
some Member States may also provide similar “introductory” meetings with regulatory experts;
(c) Certiﬁcation of quality and non-clinical data by the EMA: preferably applied before the clinical development stage, but the presence of clinical data
does not preclude this procedure;
(d) Scientiﬁc Advice procedure: can address any quality, non-clinical, and clinical question at any time point of the product development (post-marketing
advice is also available); provided by the EMA, but similar procedures can be offered in some countries by the national competent authority (NCA).
Advanced therapy medicinal product (ATMP)
Any of the following medicinal products for human use:
(a) gene therapy medicinal product,
(b) somatic cell therapy medicinal product,
(c) tissue engineered product.
Depending on the product characteristics, ATMP can be placed on the market in accordance with centralized marketing authorization procedure according
to Regulation (EC) N◦ 1394/2007 or, if applicable to product, via Hospital Exemption clause in individual Member State.
Somatic cell therapy medicinal product (CTMP)
ATMP which has the following characteristics:
(a) contains or consists of somatic cells or tissues that have been subject to substantial manipulation so that the biological characteristics, physiological
functions, or structural properties relevant for the intended clinical use have been altered; or of cells or tissues that are not intended for the same
essential function(s) in the recipient and the donor;
(b) is presented as having properties for, or is used in or administered to human beings with a view to treating, preventing or diagnosing a disease through
the action of its cells or tissues.
Centralized marketing authorization (MA)
The centralized MA procedure is required for certain categories of medicines in Europe, including the ATMPs.This procedure results in a single marketing
authorization that is valid in all EU countries, as well as in Iceland, Liechtenstein, and Norway. The European pharmaceutical regulatory framework is
applied, in particular the requirements of the Directive 2001/83/EC and the Regulation (EC) N◦ 726/2004, also the Regulation (EC) N◦ 1394/2007 with
regard to the ATMPs. The EMA is responsible for the centralized procedure for medicines and the Committee for Advanced Therapies (CAT) evaluates
ATMP submissions.
In order to address serious unmet medical needs of patients, it may be possible to obtain MA on the basis of less complete data than normally. Besides a
standardizedmarketing authorization somemedicinal product indicationsmay present a case for a conditional approval. Conditional marketing authorization
is subject to speciﬁc post-marketing obligations as set out in the Regulation (EC) N◦ 507/2006. However, such an authorization is not supposed to remain
conditional indeﬁnitely. Once the missing data are provided, it should be possible to replace it with a marketing authorization which is not conditional.
Hospital Exemption (HE)
Centralized MA is not required for such ATMPs which are prepared on a non-routine basis according to speciﬁc quality standards and are used within the
same Member State in a hospital under the exclusive professional responsibility of a medical practitioner in order to comply with an individual medical
prescription for a custom-made product for an individual patient.
Manufacturing of such ATMP products is authorized by the NCA of the Member State. The Member States have to ensure compliance with the adequate
quality standards, as well as the traceability and pharmacovigilance requirements. The HE clause is implemented through the national legislative acts and
there are differences among the HE regulations of individual Member States.
Transitional period
Advanced therapy medicinal products, excluding tissue engineered products, which were legally on the markets of the Member States in accordance
with the or the EU legislation on December 30, 2008, had to comply with the Regulation (EC) N◦ 1394/2007 no later than by December 30, 2011. Tissue
engineered products have to comply with the regulation no later than by December 30, 2012.
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clinical summaries, Module 3 provides chemical, pharmaceutical,
and biological information, Module 4 provides the non-clinical
reports, and Module 5 provides the clinical study reports. The
Regulation (EC) N◦ 1394/2007 also introduced amendments to
the Directive 2001/83/EC, for instance Article 28 added provisions
for the Hospital Exemption (HE, Article 3.7. of the consolidated
Directive 2001/83/EC).
OVERVIEW OF THE EUROPEAN REGULATORY FRAMEWORK
Directives and regulations are the two types of the EU legisla-
tive acts that form the regulatory framework for all medicines,
including cell-based products. This legal framework provides
the basis for centralized and national competencies. The direc-
tives set the general requirements for the Member States which
implement these requirements by adopting national legislative
acts. Certain variability of these implementation measures exists
amongst the Member States. The regulations have to be imple-
mented directly and uniformly, without the national legislative
acts. TheRegulation (EC)N◦ 1394/2007provides the legal basis for
a centralized authorization procedure of the ATMPs – it involves a
single scientiﬁc evaluation of the quality, safety, and efﬁcacy of the
product carried out to the highest possible standard by the Euro-
pean Medicines Agency (EMA). National (NCA) and centralized
[EMA/Committee for Advanced Therapies (CAT)] competences
at the different stages of cell therapy product development are
summarized in Table 2.
Centralized procedures are provided by the EMA which is an
interface for the cooperation and coordination of the activities
of all 27 Member States with respect to the medicinal products.
It is responsible for coordinating the existing scientiﬁc resources
for the evaluation, supervision, and pharmacovigilance of the
medicinal products. The EMA has seven committees including
the CAT as well as a number of working parties which are expert
groups with a speciﬁc scope and mandate. In addition to the
evaluation of product marketing applications, the EMA man-
dates include scientiﬁc and procedure advice, the Innovation
Task Force (ITF) meetings with product developers, coordina-
tion of the inspections of the Member States (GMP, GCP, GLP),
and other. The mandates of the EMA do not cover the follow-
ing ATMP development-related issues: pre-clinical development,
clinical trial authorization, products legally on the market during
the transitional period, HE authorization, functions of the ethics
committee (but the EMA has the expertise to evaluate ethical
issues), pricing and reimbursement of medicinal products. These
issues are regulated at the Member State level by the national
competent authority (NCA). Some states have one regulatory
ofﬁce whilst others have several NCAs that cover different reg-
ulatory tasks. The respective EU directives set the scene for the
national regulatory frameworks. The Directive 2004/23/EC (with
the implementingDirectives 2006/17/EC and 2006/86/EC) deﬁnes
the quality and safety standards for the donation, procurement,
testing, processing, preservation, storage, and distribution of
human tissues and cells. In the case of blood cells or blood
components for the ATMP manufacture, the requirements of the
Directive 2002/98/EC apply. For ATMPs that contain human cells
or tissues, Directive 2004/23/EC and 2002/98/EC derived national
provisions will apply as far as donation, procurement and testing
are concerned. The requirements of these directives donot apply to
research projects, their scope is only the tissues and cells intended
for human use. Clinical trials with ATMPs should be conducted in
accordance with the overarching principles and the requirements
laid down in the Directive 2001/20/EC on approximation of the
national laws, regulations and the administrative provisions for the
implementation of good clinical practice in the conduct of clini-
cal trials on medicinal products for human use. Compared with
the regulatory system in the US, the EMA is not “FDA of Europe”
since the FDA has a direct mandate to regulate the above men-
tioned issues and perform other tasks, including research. The
current developments indicate that the EMA is likely to acquire
more mandates in the future which will reduce the historical frag-
mentation of the European regulatory framework for medicinal
product development.
The CAT provides a centralized cell therapy product evaluation
procedure. The CAT formulates a draft opinion on the quality,
safety, and efﬁcacy of a product for the ﬁnal approval by the
Committee for the Medicinal Products for Human Use (CHMP).
The EU marketing authorization which is based on a centralized
evaluation procedure takes 210 days excluding clock-stops, it is
deﬁned in the Regulation (EC) N◦ 726/2004. The evaluation is
done by two independent (Reporter and Co-Reporter) assessor
Table 2 | Centralized and national components of the regulatory framework for ATMP development in the EU.
Type of activity Legislation NCA EMA/CAT
Cell and tissue donation, procurement, processing National Inspection, authorization n/a
Pre-clinical development National GLP inspection, consultation Certiﬁcation procedure (optional)
Clinical development National GCP, GMP inspections, authorization n/a
ATMP classiﬁcation EU Consultation Procedure/opinion
ATMP certiﬁcation EU n/a Procedure/opinion/certiﬁcate
ATMP evaluation EU n/a Procedure/opinion
Transition period EU Consultation ATMP evaluation
Hospital exemption National Consultation, GMP inspection, production license n/a
GLP, good laboratory practice; GCP, good clinical practice; GMP, good manufacturing practice.
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teams with the CAT and the CHMP representatives. The fee for
marketing authorization is reduced by 50% if the applicant is a
hospital or a small- or medium-sized enterprise and can prove
that there is particular public health interest in the ATMP con-
cerned. This is prescribed in the Article 19 of the Regulation (EC)
N◦ 2007/1394. However, even if the marketing authorization for a
cell therapy product is granted, the Regulation does not interfere
with the decisions of the Member State on whether to allow the
use of any speciﬁc type of human cells such as embryonic stem
cells or xenogeneic cells. It does not affect the application of the
national legislationprohibiting or restricting the sale, supply or use
of medicinal products containing, consisting of or derived from
particular cells. Several cell therapy products were legally on the
Member State markets before December 30, 2008. Such products
have been granted a transition period deﬁned in the Article 29 of
the Regulation (EC) N◦ 1394/2007 during which products have
to comply with the Regulation. The transition period for CTMPs
has already expired at the end of 2011, and for tissue engineered
products the transition period expires in 2012.
The evaluation-related tasks of the CAT include the classiﬁca-
tion of the advanced therapy products and certiﬁcation of their
pre-clinical data quality. Product developers have access to the
classiﬁcation procedure in order to determine whether a given
product based on cells, genes or tissues meets the scientiﬁc crite-
ria which deﬁne it as an ATMP. It is an incentive but not a legal
requirement for the applicants and an opinion is delivered within
60 days after the receipt of the request. More than 50 classiﬁcations
have been completed by 2012 and non-conﬁdential summaries
are available on the EMA website. ATMP classiﬁcation procedure
does not determine whether product dossier will be evaluated by
the centralized procedure in or it can be submitted for the HE in
Member State. However, the CAT classiﬁcation procedure opinion
is not legally binding for the NCAs in case product is submitted for
the HE. Finally, certiﬁcation of the quality and non-clinical data is
a new and unique procedure available only for the medicinal prod-
ucts of advanced therapy classiﬁcation and it is based on the Regu-
lation (EC) N◦ 668/2009. Micro businesses and SMEs developing
an ATMP can submit all the relevant quality and where available
non-clinical data to the EMA for scientiﬁc evaluation by the CAT.
It is a 90-day procedure and in the case of a favorable CAT opinion
the EMA will issue a corresponding certiﬁcate. The certiﬁcation
is not legally binding but it will facilitate the development and
improve the clinical trial andmarketing authorization applications
basedon the samedata. Only one cell therapy certiﬁcationhas been
completed since the launching of this procedure. This is possibly
due to the optional nature of the procedure and the interpretation
that the resulting opinion is not legally binding for the EMA. It is
also possible that SMEs developing cell therapy products may not
be yet fully aware of this procedure and the related potential bene-
ﬁts. It has to be emphasized that a positive outcomeof the certiﬁca-
tion procedure indicates that the regulatory agency has evaluated
and recognized the quality of non-clinical data. Certiﬁcation of
the data quality also minimizes the possibility of major objections
at the marketing application evaluation stage and may serve as an
incentive for investments in the development of cell therapy.
Upon request of the ExecutiveDirector of the EMAor the Euro-
pean Commission the CAT provides advice and scientiﬁc support
to drafting documents related to the fulﬁllment of the objectives of
theATMPregulation. On request of theEuropeanCommission the
committee provides scientiﬁc expertise and advice for initiatives
related to the development of innovative medicines and therapies
which require the expertise in advanced therapy-related scientiﬁc
areas. The activities proposed in the CAT Work programme 2010–
2015 may be of interest for theATMP stakeholders. The document
is available at the EMA website and link is provided in the refer-
ences. Considering the potential of the ATMPs and due to the lack
of product progress to the market, the CAT has adopted proactive
approach in providing the guidance tools and ensuring a dialog
with the relevant parties. A number of program activities are tar-
geted at the needs of the ATMP developers and the stakeholders
are welcome to communicate their opinion via the EMA website.
The CAT Work programme for the period of 2010–2015 is aimed
at providing positive long term impact on the advanced therapy
sector in Europe.
CONSIDERATIONS FOR DEVELOPMENT OF MSC-BASED
MEDICINES
The mesenchymal stem cells (MSCs) have produced beneﬁcial
effects in a wide range of pre-clinical development disease mod-
els, even though there are as yet no adequate explanations for
many of the effects observed (Prockop and Oh, 2012). Dur-
ing the last decade the MSC-based therapy clinical trials have
been conducted for at least a dozen of different medical con-
ditions (Wang et al., 2012). The results of clinical studies have
led to the conclusion that MSC applications have been safe and
feasible. However, the efﬁcacy often could not be convincingly
demonstrated as the therapies advanced along with the clinical
development. This is also illustrated by the absence of MSC-based
products in the European market. Only a few MSC-based cell
therapy products have been approved in other markets world-
wide. South Korea is leading with two MSC products registered
and the ﬁrst authorization granted in 2011. It might be linked to
the procedure of a conditional marketing approval in the regu-
latory framework of South Korea that allows commercial sale in
certain instances whilst pivotal trials are underway. There is also a
procedure of conditional marketing authorization in the EU pre-
scribed by theRegulation (EC)N◦ 507/2006 but certain differences
exist in the regulatory systems. With the approval from the Korean
FDA in January 2012, Cartistem has become the world’s ﬁrst allo-
genic, off-the-shelf MSC-based product. The product contains
the umbilical cord blood (UCB)-derived MSCs and it is indicated
for the treatment of traumatic and degenerative osteoarthritis.
In 2011 the Korean company FCB PharmiCell received Korean
FDA approval for commercial sale of HeartiCellgram indicated
for post-acute myocardial infarction treatment. It is autologous
bone marrow-derived MSC therapy product. The company pro-
vides 50–90 million cells (depending on the weight of the patient)
which are administered by infusion into the coronary arteries. The
regulatory approval for HeartiCellgram was granted after 6 years
of clinical trials. The company has announced that the patients
displayed a 6% improvement in the left ventricular ejection frac-
tion 6 months after one dose of HeartiCellgram. However, the
company has not published the results in a peer-reviewed jour-
nal (Wohn, 2012). It seems that a similar regulatory decision has
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been adopted for Osiris Therapeutics Inc. product Prochymal
which consists of allogenic MSCs. The company was granted
an authorization for the treatment of acute graft-vs-host disease
(GvHD) in children under Health Canada’s Notice of Compliance
with conditions (NOC/c) in May 2012. This is an authoriza-
tion to market on condition that the manufacturer undertakes
additional studies to verify the clinical beneﬁt. Such a regulatory
pathway provides access to treatments for unmet medical condi-
tions and has demonstrated the beneﬁts outweigh the risks in the
clinical trials. Overall this may represent a regulatory trend to con-
sider the evaluation procedures that could address medical needs
more efﬁciently. Adaptive licensing, e.g., conditional approvals,
would be based on stepwise learning in circumstances of acknowl-
edged uncertainty, with iterative phases of data gathering and
regulatory re-evaluation (Eichler et al., 2012). Adaptive licensing
requires a different approach from the standardized dichotomous
unapproved/approved product paradigm.
Better understanding of the regulatory framework should
improve the development strategy and create opportunities for
MSC-based therapy product authorization also in Europe. From
the regulatory perspective all MSC-based products in the EU will
be classiﬁed as ATMPs unless the developer claims that the MSCs
have been obtained without in vitro culture step. According to
the CAT opinion, the cell culture process corresponds to a “sub-
stantial manipulation” and the derived cells qualify as an active
substance of a medicinal product. The MSCs containing medic-
inal product can be classiﬁed as cell therapy or tissue engineered
product depending on the intended use and the claimed mode
of action. The addition of recombinant proteins, chemicals and
biologically active molecules in vitro to the MSCs will not change
the regulatory status of the product. Introduction of gene expres-
sion vector into MSCs does not change the ATMP status but will
result in reclassiﬁcation from the cell to gene therapy product,
since the product which may fall within the deﬁnition of the
CTMP and the gene therapy medicinal product should be con-
sidered as a latter (as deﬁned in Part IV of Annex I to Directive
2001/83/EC). The studies that report MSC clinical application
often present the development strategy decisions which could be
re-evaluated in case the overall aim was to develop a cell therapy
product. It is often reported that unmodiﬁed primary MSC cul-
tures have been used. Correspondingly, pre-clinical screening has
been absent since there was only one active substance candidate.
The rationale of the use of a particular MSC culture should be
evaluated if mesenchymal cell clinical application does not require
the same essential function as in the tissue of origin. Instead, the
MSC trials often aim to facilitate the tissue regeneration or to
achieve the immunomodulatory effect. Pre-clinical screening and
selection is an integral part of conventional medicinal product
development and there is no reason to assume that it should not
be introduced also for the cell therapy developments. With the
technology available there are several strategies that might be con-
sidered in order to introduce the MSC therapy candidate selection
step. For instance, modiﬁcation of a primary MSC population
with small chemical compounds and subsequent screening for
expression or secretome proﬁles could be considered to improve
the study design and the efﬁcacy (Ranganath et al., 2012). Genetic
modiﬁcation to express factor(s) that are expected to mediate or
enhance the therapeutic effect and characterization of transfected
clones also represents rational development (Olson et al., 2012).
The comparison of subpopulations or primary cultures of differ-
ent origin will increase the number of candidates for the screening
and has been applied for the cell-based medicinal product devel-
opment (Li et al., 2012). These examples illustrate the feasibility
of the pre-clinical screening step also for the cell-based therapies.
Whilst the screening will increase the costs and may not be attrac-
tive or necessary for the academic research activities, itmay present
a cost efﬁcient improvement for the discovery of new MSC ther-
apy candidates. It may provide beneﬁts also from novel intellectual
property acquisition perspective.
The MSC product developers are advised to start with the
EMA scientiﬁc guidelines that provide a detailed description of
the quality, safety, efﬁcacy, and pharmacovigilance issues for
CTMPs. These guidance documents include the “Guideline on
human cell-based medicinal products,” “Guideline on the safety
and efﬁcacy follow-up – risk management of advanced therapy
medicinal products,”“Guideline on strategies to identify and mit-
igate risks for ﬁrst-in-human clinical trials with investigational
medicinal products,” “Guideline on the quality, preclinical and
clinical aspects of medicinal products containing genetically mod-
iﬁed cells,” and “Reﬂection paper on stem cell-based medicinal
products.” “Guideline on the risk-based approach according to
Annex I, part IV of Directive 2001/83/EC applied to Advanced
Therapy Medicinal Products” is an important ATMP guidance
document which has been published for public discussion and
will be ﬁnalized by the end of 2012 (the e-links for all guidance
documents are provided in the references). The above-mentioned
guidance documents should be examined in detail but it is nei-
ther the scope of these documents nor is it technically feasible to
describe the whole variety of cell therapy products. Instead, the
risk analysis may cover the entire development process and an
adequate risk-based approach strategy has to be applied. Accord-
ing to the Directive 2001/83/EC, due to the speciﬁc nature of the
ATMPs, the application of a risk-based approach is encouraged
to determine the extent of quality, the non-clinical and clinical
data to be included in the marketing authorization application.
The risk analysis methodology followed, the nature of the iden-
tiﬁed risks and the implications of the risk-based approach for
the development and evaluation program has to be discussed and
the risk analysis has to be described in the product application.
For instance, if conventional pharmacological and toxicological
tests may not be considered as appropriate for a cell therapy prod-
uct, the relevant biological parameters such as the cell viability,
biodistribution, ectopic growth, and the expression patterns can
be investigated. It is acknowledged that relevant animal models
for cell therapy product and indication might not exist. Immuno-
compromised animals may have a limited value, the structural
and functional dissimilarities between the animal and human tar-
get organs/tissues may not produce relevant data. It would be
reasonable to assume that the marketing authorization and certi-
ﬁcation application evaluation will be carried out in accordance
with the risk-based approach until a certain number of products
reach the market.
The whole range of assistance procedures and initiatives avail-
able from the EMA and the NCAs should be considered (summary
www.frontiersin.org August 2012 | Volume 3 | Article 253 | 5
“ﬁmmu-03-00253” — 2012/8/13 — 14:41 — page 6 — #6
Ancans Cell therapy product regulatory framework
in Table 1). The product classiﬁcation procedure is highly
recommended at an early stage of development. This will conﬁrm
the legal framework and the relevant guidance documents can
be applied for the development. Certiﬁcation of non-clinical and
quality data should be considered since a positive outcome would
facilitate and streamline the product development for authoriza-
tion. Since there are no MSC products authorized in the EU,
certiﬁcation by the regulatory agency may encourage funding
agencies and the potential investors. Application for EMA ITF
brieﬁngmeeting deﬁnitely should be considered. The ITF provides
a multidisciplinary group that contains scientiﬁc, regulatory, and
legal competences. It is a forum for an early dialog with the appli-
cants. The ITF brieﬁng meetings are meant to complement other
regulatory procedures, such as the classiﬁcation, certiﬁcation, and
scientiﬁc advice (SA). The ITF meetings are free of charge; the
application forms and information about the procedure are avail-
able at the EMA website. The SA procedure provides considerably
more detailed information to the applicant and can be used at any
stage of the MSC product development. The procedure helps the
applicant to make sure that appropriate tests and studies are per-
formed. Consequently no major objections are likely to be raised
during the evaluation of the marketing authorization application.
Such major objections could signiﬁcantly delay the marketing of a
product andmay result in a refusal of the authorization. Adherence
to the SA recommendations can substantially increase the prob-
ability of a positive marketing outcome (Regnstrom et al., 2010).
Within the current initiative the EMA provides SA to the SMEs
for a fee reduced by 90%, and with a 65% reduction for other
applicants that develop the ATMPs. Several NCAs also have the
capacity and the expertise to provide similar advice but this has to
be conﬁrmed with the particular agency. The protocol assistance
procedure should be considered for orphan or rare disease prod-
ucts, i.e., a condition affecting no more than 5 in 10,000 people
in the EU. This procedure is available at the EMA and presents
a special form of SA. As a result the “orphan designation” may
be applied for medicinal products that meet the criteria and the
incentives for “orphan designation” include the fee reduction and
10 years of market exclusivity once authorized. Products developed
for ultra rare diseases may qualify for a marketing authorization
under exceptional circumstances which requires a less complete
data set. The following guidance document has been published
for further information: “Guideline on procedures for the grant-
ing of amarketing authorization under exceptional circumstances,
pursuant to Article 14 (8) of Regulation (EC) N◦ 726/2004.”
Alternatively, an MSC therapy product may be considered for
national authorization procedure under the HE clause in a par-
ticular Member State. In order to qualify for HE authorization,
a product has to be prepared on a non-routine basis accord-
ing to speciﬁc quality standards, and has to be used within the
same Member State in a hospital under the exclusive professional
responsibility of a medical practitioner (legal deﬁnition provided
in Table 1). The HE regulatory instrument could be in a way
perceived as adaptive licensing at the national level for advanced
therapy medicinal products. It has to be acknowledged that inher-
ent and unavoidable autologous cell material differences can make
certain cell therapy applications more similar to the develop-
ment of medical technology than to classical medicinal product
development process with standard clinical trials (Webster et al.,
2011). This does not mean that autologous cell products by def-
inition would qualify for HE approval since regulatory decision
is not based on the origin of cell material. However, autologous
products combined with complex medical procedures are more
likely to qualify for the HE due to the inherent product character-
istics. In either case the HE is still a very new regulatory procedure
which, if considered, should be discussed in advance with the
experts of an NCA. The implementation of the HE clause has
been accomplished in the majority of EU states by 2012, but the
terms and conditions of the authorization vary and each Member
State decides on the implementation tools. For instance, a recent
publication illustrates the differences between France and the UK
regarding the HE authorizations and also provides information
on several other ATMP development-related issues that are regu-
lated differently at the national level (Mahalatchimy et al., 2012).
This reference should be examined in case the application for the
HE authorization is planned in the UK or France. For instance, the
UK agency provides options for either the HE authorization or the
“Specials” exemption status according to Article 5.1. of Directive
2001/83/EC. The website of the UK NCA – Medicines and Health-
care products RegulatoryAgency (MHRA) –provides user friendly
information on the ATMP-related questions and relevant ﬂow-
charts in the section“Howwe regulate advanced therapymedicinal
products.” Information on the HE clause in Germany is available
on the website of Paul-Ehrlich-Institute (PEI) which is the Ger-
man NCA. The PEI Innovation Ofﬁce website includes summaries
in English and ﬂow-chart on how the ATMPs are regulated in
Germany (links are provided in references). GermanATMP frame-
work is reviewed and analyzed in detail in a recent publication
(Buchholz et al., 2012).
CONCLUSION
Regulatory centralization has been introduced for cell therapy
productmarketing in theEUsince 2009but the remainingnational
procedures can be quite heterogeneous. Still, general provisions in
the national legal acts are based on the EU directives and there-
fore will be common for all Member States. The EMA and NCA
guidance documents, initiatives, and interaction platforms are
available to make the regulatory framework more understand-
able and accessible for investigators both in the public and private
sectors. Good understanding of centralized and national compo-
nents of the framework will form an essential part of a product
development plan and initial shortfalls will be difﬁcult to com-
pensate at the marketing authorization application stage. It is in
the best interests of the investigators and investors to communi-
cate with the NCAs and the EMA already during early phase of
MSC product formulation. Resulting strategy improvements may
facilitate MSC-based medicine development and authorization in
the European Union.
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APPENDIX
LEGISLATIVE ACTS
Regulation (EC) N◦ 726/2004 of the European Parliament and of
theCouncil of 31March2004 layingdownCommunityprocedures
for the authorisation and supervision of medicinal products for
human and veterinary use and establishing a European Medicines
Agency. Available at: http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=OJ:L:2004:136:0001:0033:en:PDF
Regulation (EC) N◦ 507/2006 on the conditional marketing
authorisation for medicinal products for human use falling within
the scope of Regulation (EC) No 726/2004 of the European Par-
liament and of the Council. Available at: http://eur-lex.europa.eu/
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EN:PDF
Regulation (EC) N◦ 1394/2007 of the European Parliament and
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Commission Regulation (EC) N◦ 668/2009 of 24 July 2009
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therapy medicinal products developed by micro, small and
medium-sized enterprises. Available at: http://eur-lex.europa.eu/
LexUriServ/LexUriServ.do?uri=OJ:L:2009:194:0007:0010:
EN:PDF
Directive 2001/20/EC of the European Parliament and of the
Council of 4 April 2001 on the approximation of the laws, regula-
tions and administrative provisions of the Member States relating
to the implementation of good clinical practice in the conduct
of clinical trials on medicinal products for human use. Available
at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:
2001:121:0034:0044:EN:PDF
Directive 2001/83/EC of the European Parliament and of the
Council of 6 November 2001 on the Community code relating to
medicinal products for human use (consolidated). Available at:
http://ec.europa.eu/health/ﬁles/eudralex/vol-1/dir_2001_83_
cons2009/2001_83_cons2009_en.pdf
Directive 2002/98/EC of the European Parliament and of the
Council of 27 January 2003 setting standards of quality and safety
for the collection, testing, processing, storage and distribution
of human blood and blood components and amending Directive
2001/83/EC. Available at: http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=OJ:L:2003:033:0030:0040:EN:PDF
Directive 2004/23/EC of the European Parliament and of the
Council of 31March2004on setting standards of quality and safety
for the donation, procurement, testing, processing, preservation,
storage and distribution of human tissues and cells. Available at:
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:
2004:102:0048:0058:en:PDF
Commission Directive 2009/120/EC of 14 September 2009
amending Directive 2001/83/EC of the European Parliament and
of the Council on the Community code relating to medicinal
products for human use as regards advanced therapy medicinal
products. Available at: http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=OJ:L:2009:242:0003:0012:EN:PDF
GUIDANCE DOCUMENTS
Guideline onprocedures for the granting of amarketing authorisa-
tion under exceptional circumstances, pursuant toArticle 14 (8) of
Regulation (EC) N◦ 726/2004 (EMEA/357981/2005). Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/Regu
latory_and_procedural_guideline/2009/10/WC500004883.pdf
Guideline on human cell-based medicinal products (EMEA/
CHMP/410869/2006). Available at: http://www.emea.europa.eu/
docs/en_GB/document_library/Scientiﬁc_guideline/2009/09/
WC500003894.pdf
Guideline on strategies to identify and mitigate risks for ﬁrst-
in-human clinical trials with investigational medicinal products
(EMEA/CHMP/SWP/28367/07). Available at: http://www.emea.
europa.eu/docs/en_GB/document_library/Scientiﬁc_guideline/
2009/09/WC500002988.pdf
Guideline on the safety and efﬁcacy follow-up – risk manage-
ment of advanced therapy medicinal products (EMEA/149995/
2008). Available at: http://www.emea.europa.eu/docs/en_GB/
document_library/Regulatory_and_procedural_guideline/
2009/10/WC500006326.pdf
Guideline on the minimum quality and non-clinical data for
certiﬁcation of advanced therapy medicinal products (EMA/CAT/
486831/2008). Available at: http://www.ema.europa.eu/docs/
en_GB/document_library/Scientiﬁc_guideline/2010/01/
WC500070031.pdf
Guideline on the quality, preclinical and clinical aspects of
medicinal products containing genetically modiﬁed cells (EMA/
CAT/GTWP/671639/2008). Available at: http://www.ema.europa.
eu/docs/en_GB/document_library/Scientiﬁc_guideline/2012/05/
WC500126836.pdf
Reﬂection paper on stem cell-based medicinal products (EMA/
CAT/571134/2009). Available at: http://www.ema.europa.eu/docs/
en_GB/document_library/Scientiﬁc_guideline/2011/02/
WC500101692.pdf
Committee for Advanced Therapies (CAT) Work Programme
2010 – 2015 (EMA/CAT/235374/2010). Available at: http://www.
ema.europa.eu/docs/en_GB/document_library/Work_
programme/2010/11/WC500099029.pdf
Draft guideline on the risk-based approach according to Annex
I, part IV of Directive 2001/83/EC applied to Advanced Therapy
Medicinal Products (EMA/CAT/CPWP/686637/2011). Available
at: http://www.ema.europa.eu/docs/en_GB/document_library/
Scientiﬁc_guideline/2012/01/WC500120989.pdf
How we regulate advanced therapy medicinal products:
MHRA. Available at: http://www.mhra.gov.uk/Howweregulate/
Advancedtherapymedicinalproducts/Aboutadvancedtherapy
medicinalproducts/index.htm
Informal advice for the development of Advanced Therapy
Medicinal Products (ATMP): The Innovation Ofﬁce at the Paul-
Ehrlich-Institut. Available at: http://www.pei.de/cln_227/nn_
2309950/EN/infos-en/pu-en/innovation-ofﬁce/innovation-
ofﬁce-node.html?__nnn=true
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